This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lampit, M. Articles by Hochberg, Z.'e. Search for Related Content PubMed PubMed Citation Articles by Lampit, M. Articles by Hochberg, Z.'e.

Estrogen Mini-Dose Replacement during GnRH Agonist Therapy in Central Precocious Puberty: A Pilot Study

Department of Pediatrics, Rambam Medical Center, Haifa 31096; and Dana Children’s Hospital, Tel-Aviv 64239, Israel

Address all correspondence and requests for reprints to: Dr. Z. Hochberg, Pediatric Endocrinology, Rambam Medical Center, POB 9602, Haifa 31096, Israel. E mail: z_hochberg{at}rambam.health.gov.il

Abstract

During GnRH agonist therapy of patients with central precocious puberty (CPP), growth is sometimes suppressed to subnormal velocity. The working hypotheses were that estrogen levels are suppressed by GnRH agonist therapy below normal prepubertal levels, that such suppression is responsible for the slow growth of girls with CPP during GnRH agonist therapy, and that a mini-dose of estrogen replacement will normalize growth. The present pilot study examined growth and bone maturation over 2 yr in 13 patients with CPP and compared therapy with a combination of GnRH agonist and 8 µg conjugated equine estrogen (group 1) to therapy with GnRH agonist alone (group 2). Both groups had adequate suppression of gonadotropins, and E2 levels were below detection levels of our assay throughout the study period. Group 2 patients decreased their growth velocity from 2.0 ± 1.4 to -1.6 ± 1.2 SD score compared with group 1, who maintained their growth velocity of 1.3 ± 1.5 SD score and their height SD score for 2 yr (P < 0.01). In group 1 patients the ratio of the change in bone age/change in chronological age decreased from 1.2 ± 0.7 to 0.75 ± 0.3, and in group 2 patients it decreased to 0.6 ± 0.3 and 0.4 ± 0.2 (P < 0.05) during the first and second years of therapy, respectively. It is concluded on a pilot basis that estrogen suppression is responsible for the slow growth of girls with CPP during GnRH agonist therapy and that a mini-dose of estrogen replacement is safe and effective for at least 24 months in maintaining normal prepubertal growth without acceleration of bone maturation or pubertal development. The current pilot results do not suggest an indication or provide a justification for such therapy.

This article has been cited by other articles:

				L. Aksglaede, A. Juul, H. Leffers, N. E. Skakkebaek, and A.-M. Andersson The sensitivity of the child to sex steroids: possible impact of exogenous estrogens Hum. Reprod. Update, July 1, 2006; 12(4): 341 - 349. [Abstract] [Full Text] [PDF]

				A. Badaru, D. M. Wilson, L. K. Bachrach, P. Fechner, L. M. Gandrud, E. Durham, K. Wintergerst, C. Chi, K. O. Klein, and E. K. Neely Sequential Comparisons of One-Month and Three-Month Depot Leuprolide Regimens in Central Precocious Puberty J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1862 - 1867. [Abstract] [Full Text] [PDF]

				M. Weise, A. Flor, K. M. Barnes, G. B. Cutler Jr., and J. Baron Determinants of Growth during Gonadotropin-Releasing Hormone Analog Therapy for Precocious Puberty J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 103 - 107. [Abstract] [Full Text] [PDF]